Kingdon Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Kingdon Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-400,000	Closed	-$28.7M	–	78
2018 Q4	$28.7M	Buy	+400,000	New	+$32.2M	4.33%	3
2017 Q1	–	Sell	-200,000	Closed	-$11.8M	–	142
2016 Q4	$11.8M	Buy	+200,000	New	+$12.3M	0.57%	58
2015 Q4	–	Sell	-300,000	Closed	-$18.7M	–	148
2015 Q3	$18.7M	Buy	+300,000	New	+$23.6M	0.9%	35

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

CHP

Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Kingdon Capital Management's XBI Position: Q1 2017 in Review

Kingdon Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2017, closing a stake of 125,000 shares — an estimated $7.4M sold.

Kingdon Capital Management first reported a position in XBI in Q4 2016 and held it in 1 quarter. The position peaked at $7.4M in Q4 2016. 292 funds tracked by Wall St. Rank hold XBI as of Q1 2017.

Kingdon Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2017 after selling out during the quarter.
Kingdon Capital Management sold 125,000 State Street SPDR S&P Biotech ETF shares in Q1 2017, an estimated $7.4M.
Kingdon Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 1 quarter.
Kingdon Capital Management's State Street SPDR S&P Biotech ETF position peaked at $7.4M in Q4 2016.
292 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2017.

Based on Kingdon Capital Management's 13F filing for Q1 2017, filed 15 May 2017.